Eurofins Pharma Bioanalytics Services US, LLC
- UEI
- JL23CDPHLER3
- CAGE
- 7B1Z5
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
Parent
NCD8HPZK1DP4
-
Parent
NCD8HPZK1DP4
- SAM.gov registration date
- Website
- eurofinsus.com
- Founded
- 1987
- Employees
- 50K-100K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Industrials
- Commercial & Professional Services
- Professional Services
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $24,150 |
| FY2024 | $11,075 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Laboratory analysis | National Cancer Institute (NIH) | $12,075 | |
| Laboratory analysis | National Cancer Institute (NIH) | $12,075 | |
| Laboratory analysis | National Cancer Institute (NIH) | $11,075 |
Similar vendors
About the company
Eurofins Pharma Bioanalytics Services US, LLC is a foreign-owned, for-profit corporate entity registered in the System for Award Management (SAM) since January 8, 2015, with its registration set to expire on January 15, 2026. Located in St. Charles, Missouri, the company specializes in providing laboratory analysis services to federal agencies, with a primary focus on scientific and research-oriented support. While specific details about the company's full portfolio are not provided in the available data, the vendor appears to be a specialized laboratory services provider targeting scientific research institutions and government agencies.
The company has been awarded multiple federal contracts exclusively from the National Cancer Institute (NCI), all of which are purchase order contracts for laboratory analysis services. These contracts are consistently valued between $11,075.00 and $12,075.00, with performance periods ranging from June 30, 2024 to March 19, 2026. Each contract follows a firm fixed-price structure and does not utilize any specific set-aside designations. The laboratory analysis services appear to be targeted toward supporting scientific research, with a specific geographic focus on Rockville, Maryland. None of the current contract awards indicate the use of federal contract vehicles, prime contract awards, or grant prime awards, suggesting Eurofins Pharma Bioanalytics Services US, LLC operates as a direct service provider to the NCI for specialized laboratory analysis needs.
Quick answers
Is Eurofins Pharma Bioanalytics Services US, LLC registered in SAM.gov?
Eurofins Pharma Bioanalytics Services US, LLC's SAM.gov registration expired on January 15, 2026.
What is Eurofins Pharma Bioanalytics Services US, LLC's CAGE code?
Eurofins Pharma Bioanalytics Services US, LLC's CAGE code is 7B1Z5, and its Unique Entity ID (UEI) is JL23CDPHLER3.
How much has Eurofins Pharma Bioanalytics Services US, LLC received in federal contracts?
Federal contracts obligated $24,150 to Eurofins Pharma Bioanalytics Services US, LLC in fiscal year 2025 and $35,225 in fiscal years 2023 through 2027.
What is Eurofins Pharma Bioanalytics Services US, LLC's most recent federal award?
Eurofins Pharma Bioanalytics Services US, LLC's most recent federal contract award is Laboratory analysis (75N91025P00244), from National Cancer Institute (NIH), on March 20, 2025.
On GovTribe
See Eurofins Pharma Bioanalytics Services US, LLC's full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors